RNA therapeutics have moved from proof of concept to an established drug class in under a decade, with six approved siRNA drugs and multiple mRNA vaccines now on the market. Yet quantifying these molecules remains far from routine: oligonucleotide therapeutics built from a polyanionic duplex or a capped, polyadenylated transcript each demand a different bioanalytical answer, and no single platform covers every need across discovery, pharmacokinetics (PK), and regulatory submission.
Bioanalytical challenges specific to siRNA and mRNA: nuclease instability, strand selectivity, and matrix binding
Native oligonucleotides are rapidly degraded by exo- and endonucleases, which is why nearly every approved siRNA therapeutic candidate carries phosphorothioate linkages, 2′-fluoro or 2′-O-methyl modifications, or a GalNAc siRNA conjugate for hepatocyte-targeted delivery. Quantification itself raises further modality-specific questions:
- Strand selectivity: siRNA is double-stranded, and only the antisense (guide) strand is typically monitored for siRNA quantification, since the sense strand degrades differently and can fall below detection entirely.
- Matrix binding: once loaded into the RNA-induced silencing complex, the antisense strand associates tightly with Argonaute 2 (Ago2), so free and RISC-bound siRNA behave as distinct pools.
- mRNA-specific complexity: larger than siRNA and typically delivered via lipid nanoparticle mRNA delivery encapsulation, mRNA integrity depends not just on sequence but on the 5′ cap and 3′ poly(A) tail that determine translational activity.
- Conjugate complexity: antibody-siRNA conjugates add a protein component, multiplying the analytes an RNA interference therapeutics program may need to track in one PK study.
LC-MS/MS strategies for siRNA and mRNA quantification: ion pair chromatography, hybridization capture and detection
LC-MS/MS siRNA analysis typically relies on ion-pair reversed-phase (IP-RP) chromatography. An alkylamine reagent pairs with hexafluoroisopropanol as a volatile counterion to hold onto the negatively charged strand so it can be detected in negative mode.
When sensitivity isn’t enough on its own, hybrid workflows add a capture step before the LC-MS run: an antibody or probe pulls the target out of serum or plasma first, so only the antisense strand is eluted and quantified. This same idea extends to antibody siRNA conjugate bioanalysis, where an anti-conjugate antibody captures the intact species and heat releases the antisense strand for quantification, an approach recently qualified in a mouse serum PK study (Song & Yuan, 2025), where capture antibody amount, reagent lot-to-lot variation, and elution temperature were the variables that determined whether the assay held up.
Detection itself typically runs in one of two modes. MRM (multiple reaction monitoring), the standard on triple-quadrupole instruments, tracks a fixed precursor-to-fragment transition and suits fast, routine quantification once a study is underway. HRMS (high-resolution mass spectrometry) instead captures the full isotope and charge-state pattern, trading some speed for the selectivity needed to identify metabolites or troubleshoot an assay, making it the better fit earlier in a program, before every question has an answer yet.
For mRNA quantification preclinical work, the question shifts from strand identity to structural integrity: RNase digestion mapping confirms sequence, while ion-pairing RPLC characterizes cap efficiency and poly(A) tail heterogeneity.
Comparing bioanalytical platforms for RNA therapeutics: LC-MS/MS vs. hybridization ELISA vs. RT-qPCR
No single platform wins on every metric. Head-to-head comparisons using the same siRNA analyte across hybrid LC-MS, SPE-LC-MS, hybridization ELISA (HELISA), and stem-loop RT-qPCR RNA therapeutics assays show a consistent trade-off:
- Hybrid LC-MS offers the highest specificity: it’s the only platform that can tell the parent drug apart from metabolites. That precision is worth the extra development time when the distinction makes a difference.
- SL-RT-qPCR is the most sensitive and fastest of the four, but its primer-based design can’t distinguish drug from closely related metabolites.
- Hybridization ELISA siRNA assays sit close to RT-qPCR: sensitive and quick, but built around a capture probe, so specificity and metabolite blindness are the trade-off.
- SPE-LC-MS skips the capture-reagent step entirely, avoiding the extra reagent validation that hybrid workflows require, though this simpler workflow comes with lower sensitivity than the other three.
All four platforms produced comparable concentration-time profiles when tested side by side: none is simply “better.” The right choice depends on what the study needs: sensitivity, specificity, throughput, or metabolite resolution.
PK study design for RNA therapeutics: tissue distribution, target engagement, and key bioanalytical endpoints
siRNA pharmacokinetics follow a distinct pattern from small molecules: rapid systemic clearance contrasts with prolonged tissue accumulation, particularly in the liver for GalNAc-conjugated siRNAs. A robust RNA therapeutic PK study typically captures:
- Plasma and tissue concentration-time profiles, since volume of distribution, half-life, and protein binding vary widely across approved siRNA drugs.
- siRNA tissue distribution at the organ level, using QWBA, RT-qPCR, FISH, bDNA1, or mass spectrometry depending on modality.
- Target engagement and metabolites: Ago2/RISC pulldown shows whether the antisense strand is actually loaded into the active silencing complex, not just present in the sample. Metabolite monitoring matters too: for givosiran, its main 3′-truncated metabolite has been measured at roughly half the concentration of the parent drug.
1 QWBA: quantitative whole-body autoradiography; RT-qPCR: reverse transcription quantitative polymerase chain reaction; FISH: fluorescence in situ hybridization; bDNA: branched DNA assay.
Regulatory bioanalytical method validation for RNA therapeutics: ICH M10 requirements and CRO support
ICH M10 bioanalytical method validation principles (selectivity, accuracy, precision, matrix effect, stability, calibration range) apply to RNA therapeutics as to any chemical or biological drug. But the guideline only structures validation around two categories: chromatography and ligand binding assays, and neither cleanly covers hybrid LC-MS methods that combine both. That gap means sponsors decide for themselves which criteria apply, a judgment call ICH M10 itself acknowledges by encouraging applicants to consult regulators whenever an alternate validation approach is used.
Making that call well is exactly where siRNA drug development and mRNA drug development programs benefit from experience that’s already been through it. A CRO with expertise in oligonucleotide bioanalysis that has developed and defended hybrid methods across RNA modalities knows which validation elements matter most for each platform and how to frame a siRNA and mRNA regulatory submission so gaps in the guideline don’t become gaps in the data package.
At AMSbiopharma, our nucleic acid bioanalysis and gene therapy team supports siRNA and mRNA programs across the full development cycle, from early preclinical PK/TK bioanalysis through Chemistry, Manufacturing, and Controls (CMC) characterization and regulatory submission, with ICH M10-compliant methods across plasma, serum, tissue, and Cerebrospinal Fluid (CSF).
References
Agrawal K, Calliste LK, Ji S, Xu S, Ayers SA, Jian W. Comparison of multiple bioanalytical assay platforms for the quantitation of siRNA therapeutics. Bioanalysis. 2024;16(13):651-667. doi: 10.1080/17576180.2024.2350266
Jo SJ, Chae SU, Lee CB, Bae SK. Clinical Pharmacokinetics of Approved RNA Therapeutics. Int J Mol Sci. 2023 Jan 1;24(1):746. doi: 10.3390/ijms24010746
Song Z, Yuan L. A Novel Hybrid LC-MS/MS Methodology for the Quantitative Bioanalysis of Antibody-siRNA Conjugates. Anal Chem. 2025 Sep 16;97(36):19570-19577. doi: 10.1021/acs.analchem.5c02727
Thayer MB, Lade JM, Doherty D, Xie F, Basiri B, Barnaby OS, Bala NS, Rock BM. Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics. Sci Rep. 2019 Mar 5;9(1):3566. doi: 10.1038/s41598-019-40187-4
Vervaeke P, Borgos SE, Sanders NN, Combes F. Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics. Adv Drug Deliv Rev. 2022 May;184:114236. doi: 10.1016/j.addr.2022.114236.
